ProCE Banner Activity

De-Escalating Therapy for HER2-Positive Early Breast Cancer: Where Do We Stand Today?

Clinical Thought
Considering the Persephone and PerELISA trial results, should we change our practices with HER2-targeted therapies for our patients with HER2-positive early breast cancer?

Released: June 22, 2018

Expiration: June 21, 2019

No longer available for credit.

Share

Faculty

Frankie Ann Holmes

Frankie Ann Holmes, MD, FACP

Medical Oncologist
US Oncology/Texas Oncology
Houston, Texas

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

Genentech TEXT Only

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Frankie Ann Holmes, MD, FACP

Medical Oncologist
US Oncology/Texas Oncology
Houston, Texas

Frankie Ann Holmes, MD, FACP, has no real or apparent conflicts of interest to report.